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Abstract
Several studies aimed to disentangle whether pregnancy influences the growth of uterine fibroids but results were
inconsistent. In this study, we speculated that fibroid enlargement during pregnancy may not be linear and we
hypothesized that this phenomenon may mainly occur during initial pregnancy. To test this hypothesis, we set up a
prospective cohort study of women with fibroids undergoing IVF. Cases were women achieving a viable pregnancy.
Controls were the subsequent women with fibroids but failing to become pregnant. Twenty-five cases and 25 controls were
recruited. The total number of fibroids in the two groups was 46 and 41, respectively. The mean 6 SD diameter of the
fibroids was 17610 and 20611 mm, respectively (p = 0.18). A statistically significant enlargement emerged exclusively in
pregnant women. The median (Interquartile Range) modification of the diameter of the lesions in cases and controls was
+34% (+6%/+65%) and +2% (26%/+12%), respectively (p,0.001). The median (Interquartile Range) modification of the
volume of the lesions was +140% (+23%/+357%) and 0% (218%/+37%), respectively (p,0.001). In pregnant women, we
failed to document any significant correlation between the magnitude of the growth and ovarian responsiveness to hyper-
stimulation, suggesting that steroids hormones are not the unique factors involved. In conclusion, fibroids undergo a rapid
and remarkable growth during initial pregnancy. Reasons behind this phenomenon remain to be clarified. The early rise in
steroids hormones during early pregnancy may not be sufficient to explain the process. Other pregnancy-related hormones
and proteins may play also key roles.
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Introduction
The influence of pregnancy on uterine fibroids is debated for up
to three decades. Several studies aimed to disentangle whether
pregnancy determine the growth of these lesions but evidence is
inconsistent and a firm conclusion has yet to be reached [1–7].
Differences in study designs and population studied may explain
these discrepancies. Of particular relevance here is the time points
of the ultrasound assessments since the pattern of fibroid growth
during pregnancy may not be linear.
In this study, we hypothesized that fibroid growth may mostly
occur during early pregnancy. Few small studies evaluated the
impact of initial pregnancy and the results are conflicting [3,5,6]
(Table 1). To shed more light on this topic, we focussed on women
achieving pregnancy through IVF since this condition offered us
the unique opportunity to prospectively obtain precise data on the
presence and dimension of the fibroids immediately before the
advent of pregnancy and to monitor their modification very early
during pregnancy. Noteworthy, we recently demonstrated that
fibroid growth is not affected by controlled ovarian hyperstimu-
lation for IVF, thus protecting our study design from the
theoretical confounding effect of elevated sex steroids hormones
[8].
Materials and Methods
Patients who were selected for IVF-ICSI between January 2012
and November 2012 at the Infertility Unit of the Fondazione Ca’
Granda, Ospedale Maggiore Policlinico were considered for study
entry. Women were eligible if they were diagnosed at least one
uterine fibroid with a mean diameter $10 mm prior to enter the
cycle. Women carrying more than four myomas were excluded.
Patients with submucous fibroids encroaching on the cavity line,
those with at least one fibroid with a diameter .50 mm and those
with fibroid-related bleeding were also excluded and advised to
have myomectomy. Difficult sonographic evaluation of the
characteristics of the uterus and the presence of suspected
adenomyosis were additional exclusion criteria. Cases were
women achieving a viable pregnancy as assessed 4–5 weeks after
embryo transfer. Controls were the subsequent women with
fibroids performing embryo transfer but failing to become
pregnant. Women with early abortion or ectopic pregnancy were
excluded. The local Institutional Review Board ‘‘Fondazione Ca’
Granda, Ospedale Maggiore Policlinico’’ (N. 2413) approved the
study and all recruited patients signed an informed consent.
Selected patients underwent transvaginal ultrasound between
day 1 and day 8 of the cycle during the month preceding the
beginning of hyperstimulation. The precise location and dimen-
sion of all the visible myomas were recorded at this time. Even if
the presence of at least one fibroid with a mean diameter$10 mm
was an inclusion criterion, concomitant fibroids of smaller size
were also measured and studied provided that the total number
per woman did not exceed four. Hystero-sonography was done if
necessary to rule out submucosal location. Pregnant patients were
systematically scanned 4–5 weeks after embryo transfer and were
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definitely enrolled in the study only if the US scan demonstrated
the presence of a viable embryo. The second US assessment of the
precise location and dimensions of the fibroids was performed at
this time. Controls were matched to cases by study period. They
corresponded to the subsequent women with fibroids performing
embryo transfer but failing to become pregnant (negative human
Chorionic Gonadotropin-hCG assessments at +14 and +16 days
after oocytes retrieval). Similarly to cases, they were scheduled a
US assessment to evaluate the fibroids 4–5 weeks after the embryo
transfer. None of women who failed to achieve pregnancy received
estroprogestins or progestins in the period between the embryo
transfer and the following second ultrasound assessment. Sono-
graphic appearence of myomas was defined as symmetrical, well-
defined, hypoechoic and heterogeneous masses [9]. Three
perpendicular diameters (d1, d2, d3) were measured for each
myoma. The diameter of the lesions used for the analysis
corresponded to the mean of these three diameters. The volume
was calculated based on the following formula: 4/3*p*(d1*d2*d3)/
8. The precise location of the lesion was recorded in details to
allow for paired analyses. A myoma with .50% of its diameter
bulging out of the uterine contour line was defined as subserous.
Intramural fibroids were those mostly within the uterine shape.
Myomas distorting the cavity line were defined as submucosal and,
as mentioned earlier, patients with these lesions were excluded
from the study. All scans were performed by three experienced
physicians engaged for a long time in gynecological ecographies
and who were blinded to the prior condition of the women. The
localization of every myoma was described in details based on
their location within the uterine wall (subserous or intramural) and
referring to the three anatomical planes (sagittal, coronal and
transverse planes). Moreover, lesions were graphically recorded on
a rough sketch and, if deem useful to avoid any mismatching,
pictures were taken and stored to solve possible inconsistencies.
Preliminary experiments on 10 volunteers with fibroids showed an
inter- and intra-observer variability for the measurement of the
diameter of the myomas both consistently below 20%. They both
rose to 100% when considering the number of lesions.
Patients selected for IVF-ICSI were monitored and managed
according to a standardized clinical protocol as reported elsewhere
[10]. Briefly, the dose of gonadotropins was determined on an
individual basis according to the characteristics of the patients as
age, serum hormonal levels and antral follicles count. Patients
underwent serial transvaginal ultrasound and hormonal monitor-
ing during hyperstimulation. When three or more leading follicles
with a mean diameter .18 mm were visualized, 250 mg of
recombinant hCG was administered s.c. Oocyte retrieval was
performed transvaginally 36 hours after the hCG injection.
Embryo transfer was performed 48–72 hours after the oocyte
collection. Luteal phase support with progesterone 200 mg
intravaginally twice a day was started on the day of oocytes
retrieval and discontinued after 14 days regardless of the result of
serum hCG assessment (pregnant and non-pregnant women thus
received the same treatment). Cycles were cancelled because of
poor or hyper-response. We defined hyper-response as a serum
estradiol level greater than 4000 pg/ml and/or more than 20
follicles identified at ultrasound scan before hCG administration.
Poor response was defined by the ecographic evidence of fewer
than 3 follicles during ovarian hyperstimulation. Serum hCG
evaluations to assess pregnancy was performed at +14 and +16
days after oocytes retrieval. Clinical pregnancy was defined as the
ultrasonographic demonstration of an intrauterine gestational sac
containing a viable embryo 4–5 weeks after embryo transfer.
Data Analysis was performed using the Statistics Package for
Social Sciences (SPSS 18.0, Chicago, IL). The diameter of the
fibroid before and after treatment was compared using the paired
Student t-test and data is reported as mean 6 SD. The volume of
the fibroid before and after treatment was compared using the
Wilcoxon paired test and data is reported as median (IQR:
Interquartile Range). Comparisons of the baseline characteristics
between the two groups were done using the unpaired Student t-
test, the Mann-Whitney test or the Fisher Exact test, as
appropriate. Probability values ,0.05 were considered statistically
significant. The sample size was calculated setting the type I and
type II errors at 0.05 and 0.20 respectively and based on a per
patient basis (thus initially assuming that there was only one lesion
per patient). We stated as clinically relevant a relative increase in
diameter of 30%. Based on an expected mean 6 SD diameter of
the fibroids in our population of 22610 mm [10], the total
number of patients to be enrolled was of about 50 women (25 cases
and 25 controls).
Results
Twenty-five women with fibroids achieving pregnancy through
IVF were selected. Three of them were twin pregnancies. They
were matched to 25 women with fibroids failing to become
pregnant. Additionally, we monitored fibroid size modification in
an eligible woman who became pregnant spontaneously before
initiating the treatment cycle. She was carrying one single
intramural fibroid. The diameter of the lesion grew from 20 to
31 mm and the volume passed from 3.8 to 15.0 ml. This case was
however excluded from the analysis to prevent confounders.
Baseline characteristics of the two study groups are shown in
Table 2.
The total number of fibroids in pregnant and non-pregnant
women were 46 and 41, respectively. The number of women
carrying one, two, three and four fibroids were 14 (56%), 4 (16%),
4 (16%) and 3 (12%) and 15 (60%), 4 (16%), 6 (24%) and 0 (0%),
respectively (p = 0.41). They were intramural and subserosal in 23
(50%) and 23 (50%) and in 28 (68%) and 13 (32%) cases,
respectively (p = 0.13). The number of lesions at baseline and at
second assessment coincided in all women. The mean 6 SD
diameter of the fibroids was 17610 and 20611 mm, respectively
Table 1. Studies evaluating fibroids size before and during pregnancy.
Study
N. women
(lesions) Recruitment time Results
Rosati et al., 1992 12 (12) Winthin 4 months prior to pregnancy Significant increase in volume (+8%, p,0.001).
Neiger et al., 2006 11 (n.r.) Within 6 months prior to pregnancy Prepregnant size 88664% of the pregnant size (p = ns)
Ozturk et al., 2009 9 (n.r) n.r. No significant modifications but precise data not shown
n.r.: not reported.
doi:10.1371/journal.pone.0085933.t001
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(p = 0.18). The mean 6 SD diameter of the larger lesion per
woman was 20610 and 22612 mm, respectively (p = 0.70). The
median (IQR) volume of the lesions was 1.6 (0.5–5.5) and 2.6 (0.7–
7.5) ml, respectively (p = 0.12). The median (IQR) volume of the
larger lesion per woman was 2.7 (0.8–11.4) and 3.9 (0.8–16.0) ml,
respectively (p = 0.79).
The modification of the fibroid in pregnant and non-pregnant
women is shown in Table 3. A statistically significant increase
emerged exclusively in the pregnant group (p,0.001 for all
variables). All the data were transformed into percentage of
modification in order to allow inter-group comparisons. The
median (IQR) modification of the diameter of all the lesions in
pregnant and non-pregnant women was +34% (+6%/+65%) and
+2% (26%/+12%), respectively (p,0.001). The median (IQR)
modification of the diameter of the larger lesion in pregnant and
non-pregnant women was +28% (+6%/+49%) and 0% (27%/
+3%), respectively (p,0.001). The median (IQR) modification of
the volume of all the lesions in pregnant and non-pregnant women
was +140% (+23%/+357%) and 0% (218%/+37%), respectively
(p,0.001). The median (IQR) modification of the volume of the
larger lesion in pregnant and non-pregnant women was +108%
(+19%/+214%) and 0% (222%/+15%), respectively (p,0.001).
These results are illustrated in Figure 1.
In order to investigate whether ovarian hyperstimulation played
a role in influencing the growth of the fibroids within the group of
pregnant women, we performed a correlation between the
percentage of volume growth of all lesions and serum AMH,
day 3 serum FSH, total dose of gonadotropins administered,
duration of stimulation, serum estrogen at the time of hCG
administration and the number of oocytes retrieved. The
Spearman correlation coefficients were 20.16 (p= 0.42), 20.19
(p = 0.22), 20.01 (p = 0.95), +0.13 (p = 0.40), 20.11 (p= 0.57) and
+0.07 (p= 0.65), respectively.
In order to evaluate whether the enlargement of the fibroids was
related to the initial dimension of the lesions, we performed a
correlation between the percentage of volume growth of all lesions
and their initial dimension. The Spearman correlation coefficient
was 20.28 (p = 0.009). Finally, we compared the modification of
fibroids in twin pregnancies (5 lesions) and singleton pregnancies
(41 lesions) and no significant differences emerged (data not
shown).
Discussion
Fibroids dramatically enlarge during initial pregnancy. In this
study, we observed that the volume of the fibroids more than
double within 6–7 weeks’ gestation. The magnitude of the growth
is remarkable and the difference is highly statistically significant.
This effect appears particularly evident for smaller lesions. The
discrepancy with the few available evidence (Table 1) is
presumably related to a type I error and possibly also to
inaccuracies in fibroids measurement [3,5,6]. In fact, the larger
available study included only twelve women [3] and none of these
studies was specifically designed to address the growth of fibroids
during initial pregnancy. They were actually conceived to observe
the modification of these lesions during the course of pregnancy.
Table 2. Baseline characteristics of the study groups.
Characteristics Pregnant women Non pregnant women p
n=25 n=25
Age (years) 36.763.4 37.263.8 0.61
BMI (Kg/m2) 22.562.8 23.463.8 0.33
Previous pregnancies 9 (36%) 10 (40%) 1.00
Previous myomectomy 2 (8%) 4 (16%) 0.67
Previous IVF cycles 10 (40%) 9 (36%) 1.00
Duration of infertility (months) 57625 49623 0.28
Day serum FSH (IU/ml) 7.762.2 7.763.2 0.95
Serum AMH (ng/ml) 2.361.6 1.962.2 0.45
Indication to IVF-ICSI 0.11
Male factor 12 (48%) 8 (32%)
Tubal factor/endometriosis 4 (16%) 6 (24%)
Unexplained 6 (24%) 2 (8%)
Mixed 3 (12%) 9 (36%)
Protocol of ovarian stimulation 1.00
Long protocol 13 (52%) 13 (52%)
GnRH antagonists 7 (28%) 6 (24%)
Flare-up 5 (20%) 6 (24%)
Duration of stimulation (days) 10.261.6 10.361.9 0.81
Total dose of FSH (IU) 237361010 300961294 0.06
Serum estrogens at hCG administration (pg/ml) 243261139 199561088 0.27
Total number of oocytes retrieved 11.565.0 5.564.0 ,0.001
Number of embryos transferred 2.260.5 1.560.6 ,0.001
Data is reported as mean 6 SD or median (Interquartile range) or number (%) as appropriate.
doi:10.1371/journal.pone.0085933.t002
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Women with prepregnant information on the fibroids were
included only occasionally and data on the prepregnant dimension
of the lesions was presumably collected retrospectively.
Studies supporting a pregnancy-related growth of fibroids
generally claimed a crucial role of sex steroids hormone
[3,7,11,12]. Estrogen has been considered to be the primary
growth promoter of fibroids and there is also convincing evidence
that the maintenance and growth of these lesions is progesterone
dependent [12]. Noteworthy, selective progesterone-receptor
modulators have been shown to effectively shrink fibroid size
[13,14]. However, it is unlikely that sex steroids are the unique
actors involved. In fact, estrogen and progesterone raise progres-
sively but consistently during pregnancy reaching a serum
concentration of up to 15–20 ng/ml and 120–150 ng/ml in the
last trimester, respectively [15,16] In contrast, fibroids growth does
not follow a similar pattern. Albeit available evidence is
contrasting, the emerging vision is that fibroid growth during
pregnancy is, if any, not linear. De Vivo et al. and Rosati et al.
reported a deceleration of the growth rate during the second part
of pregnancy [3,7]. Lev-Toaff et al. observed an increase in size
during the second trimester only in small fibroids whereas all
lesions decreased in size in the third trimester regardless of their
dimension [1]. Moreover, three studies failed to document any
modification [2,4,6] and Hammoud et al who recruited women
late during pregnancy (16–19 weeks) observed a progressive
reduction in the dimension of fibroids [4]. Overall, regardless of
the precise pattern of change, it can be consistently concluded
from the literature that the modification of the fibroids is not
directly related to the increase in serum estrogen during
pregnancy. Our results are also consistent with a non-exclusive
role of sex steroids. We observed a marked increase in size during
early pregnancy when estrogens and progesterone are still low and
we failed to document any correlation between serum estrogen at
the time of hCG administration and the growth of the fibroids.
Sex steroids are not the unique hormones that markedly modify
with the advent of pregnancy. A plethora of other hormones and
proteins secreted by the fetal, the placental and the maternal
compartments markedly rise during early pregnancy [16].
Noteworthy, it cannot be excluded that these substances may also
have a synergic effect on fibroid growth. The potential detrimental
effects of all these compounds and their combination have not
been systematically evaluated. It is beyond the scope of this article
to discuss all of them. However, we herein speculate that hCG
may be one of the most significant factors involved. The striking
enlargement of fibroids mainly during initial pregnancy may
indeed be driven by the typical rapid exponential raise in serum
hCG and the particular kinetic of its receptor. The hypothesis of
an effect of hCG on fibroid growth is actually not novel and there
are convincing in vitro studies supporting this possibility. The
presence of functional LH-hCG receptors on fibroids has been
repeatedly demonstrated [17,18]. Moreover, functional studies
showed that hCG increases fibroid cell number both directly [19]
and through an autocrine/paracrine effect mediated by PRL
secretion [17,20]. Interestingly, this effect appears to be extremely
rapid. Horiuchi et al. observed that hCG determines an up to
500% increase in the number of leyomyoma cells after three days
of incubation when compared to cells incubated with medium
without hCG. Albeit still significant, this effect becomes less
evident after 9 days of incubation since at this time the difference
dropped to about +200% [21]. It can be stated that, similarly to
Figure 1. Modification of the dimension of the fibroids. The
dotted and white box plots refer to pregnant and non-pregnant
women, respectively. All comparisons between fibroids from pregnant
and non-pregnant women resulted statistically significant (p,0.001).
Statistical tests used were the paired Student t-test to compare the
diameters and the non-parametric Wilcoxon paired test to compare the
volumes.
doi:10.1371/journal.pone.0085933.g001
Table 3. Modification of the dimension of the fibroids in the study groups.
Pregnant women Non-pregnant women
N Before After p N Before After p
Diameters (mm)
Total 46 17610 23613 ,0.001 41 20611 20610 0.39
Larger lesion 25 20610 26614 ,0.001 25 22612 21611 0.20
Volumes (mL)
Total 41 1.6 (0.5–5.5) 5.2 (1.4–14.7) ,0.001 41 2.6 (0.7–7.5) 2.7 (0.8–9.7) 0.68
Larger lesion 25 2.7 (0.8–11.4) 7.8 (2.3–17.4) ,0.001 25 3.9 (0.8–16.0) 4.0 (0.7–14.2) 0.38
Data is reported as mean 6 SD for the diameters and as median (Interquartile range) for the volumes.
Comparisons were made using the paired Student t-test and the Wilcoxon test for paired data for the diameters and the volumes, respectively.
doi:10.1371/journal.pone.0085933.t003
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what occurs in vivo in the primate corpus luteum, the LH-hCG
receptor in leiomyoma cells requires the exponential growth of
hCG to maintain its stimulating effect. It is indeed well-established
that primate corpus luteum becomes less sensitive to LH as the
luteal lifespan progresses [22]. More robust luteotropic stimulus in
the form of exponential rising levels of LH/hCG is required to
extend the functional lifespan of the primate corpus luteum in
early pregnancy until luteal activities are assumed by the placenta
[22]. Future studies evaluating at short intervals (1–2 weeks)
fibroids size modifications from embryo implantation to the end of
the first trimester and correlating these changes to serum hCG are
required to further support our view.
If confirmed, this hypothesis may open also new therapeutic
scenarios. Indeed, the critical role of hCG in this context may also
explain the rapid growth of fibroids that more frequently occurs in
perimenopause [23]. Women in this period of their reproductive
life are typically exposed to episodic consistent raises in
gonadotropins and fibroids may receive relevant growing stimuli
during these LH peaks [24]. This situation is radically different
from the post-menopausal period (typically characterized by
fibroids regression) when gonadotropins are steadily high and
the promoting effect of estrogens is absent. On this basis, one may
speculate that a long term administration of estroprogestins in
women during premenopause may prevent possible episodic
consistent raises in gonadotropins and the consequent growth of
leiomyoma. Clinical evidence is however warranted to support this
hypothesis.
Some limitations of our study should be recognized. First of all,
we included women who underwent IVF and a confounding effect
of controlled ovarian hyperstimulation cannot be excluded.
However, we deem this limit of mild relevance for several reasons.
We previously demonstrated that fibroids were unchanged in
women with these lesions who underwent IVF and failed to
become pregnant [8]. This observation was confirmed in the
present study when the ultrasound assessment was done earlier, i.e.
4–5 weeks after oocytes retrieval rather than 3–9 months later. In
this regard, it has however to be recognized that the magnitude of
ovarian responsiveness was milder in the control group. This was
expected since ovarian reserve and thus responsiveness to hyper-
stimulation is a critical factor in influencing the chances of
pregnancy. One may argue that the lower response in the control
women may explain the lack of a stimulatory effect. At least, two
arguments argue against this possibility. Firstly, in non-pregnant
women, the size of the lesions remained identical. If ovarian hyper-
stimulation does a play a role, at least a trend toward enlargement
should have emerged but this did not occur in both the present
data and in our previous study [8]. Secondly, and most
importantly, in the group of pregnant women, we failed to
observe any correlation between fibroids growth and variables of
ovarian responsiveness to hyper-stimulation such as in particular
serum estrogens at the time of hCG administration. This latter
observation is of critical relevance since it tends to rule out also a
second possible criticism, i.e. that the observed impressive rapid
fibroid growth may be unique to IVF women. Indeed, women in
the control group failed to become pregnant and it may be argued
that using non-pregnant women as comparators may not fully
overcome the confounding effect of ovarian hyper-stimulation. In
other words, ovarian hyper-stimulation may influence fibroid
growth only if pregnancy occurs. In fact, the hormonal status in
terms of estrogens and progesterone levels markedly differ in
women achieving pregnancy spontaneously and in those becoming
pregnant through IVF. The elevated number of developing
follicles results in more corpora lutea and higher circulating
estrogens and progesterone levels. The above mentioned lack of
any correlation between ovarian response and fibroid growth
however argues against this criticism. Moreover, albeit anecdotal,
a relevant increase in fibroid size was observed in the unique
recruited woman who became pregnant spontaneously before
starting the ovarian hyperstimulation. Further evidence in a series
of women achieving pregnancy spontaneously is however required
for definite generalizability of our findings to women with fibroids
achieving pregnancy spontaneously.
A second possible concern is related to the sonographic
assessment. Our diagnosis of fibroids lacks histological confirma-
tion and the process of lesions measurement was inevitably
exposed to a certain degree of inaccuracy. Again, we do not
estimate that this limitation should question the validity of our
conclusions for several reasons. The diagnosis of fibroids using
ultrasounds is validated in clinical practice [9] and this diagnostic
tool is used by all previous studies on fibroids modification during
pregnancy [1–7]. Moreover, to further reduce the risk of
misdiagnosis, all scans were performed by few and experienced
physicians and unclear cases as well as women with more than four
lesions were excluded. Noteworthy, the number of lesions at
baseline and at the time of second assessment coincided in all
studied women. Finally, even if some inaccuracies in volume
assessment cannot be excluded, the use of blinded operators and
the magnitude of the observed differences tend to exclude a critical
role of this limitation.
In conclusion, uterine fibroids rapidly growth during initial
pregnancy. Physicians should be aware of this possibility and
women can be reassured since this change is expected. This results
needs however definite confirmation in a population of women
achieving pregnancy spontaneously. Further evidence is also
required to better draw the precise pattern of fibroids modification
during the subsequent prosecution of pregnancy and to assess
whether our findings may be of therapeutic interest.
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